EUCTR2021-004469-11-FR进行中（未招募）1 期
PhagoDAIR I: A Phase I/II Multicenter, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Phage Therapy in Patients with Hip or Knee Prosthetic Joint Infection due to Staphylococcus aureus Treated with DAIR and Antibiotic Therapy. - PhagoDAIR I
PHERECYDES PHARMA0 个研究点目标入组 80 人开始时间: 2021年10月8日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1.Male or female = 18 years
- •2.Staphylococcus aureus monomicrobial knee or hip PJI ?3 months after prosthesis implantation with clinical signs of infection and with indication of DAIR with direct closure and Suppressive Antibiotics Therapy (SAT)
- •3.Staphylococcus aureus in joint fluid during the pre-inclusion period or in case of relapse of under antibiotics therapy in the first 6 months after a DAIR
- •4.Without preoperative diagnosis of superinfection due to another pathogen
- •5.Phagogram displaying the susceptibility of the strain to at least one of the phages.
- •6.Patient with a life expectancy of 2 years and more as determined by the principal investigator
- •7.Females of childbearing potential/Sexually active males with partner of childbearing potential: commitment to consistently and correctly use an acceptable method of birth control (oral, transdermal, systemic or implant contraception birth control, intrauterine devices, diaphragm or condoms) for 1 month after the last study drug administration
- •8.Females of non-childbearing potential: either surgically sterilized or at least 1 year postmenopausal (amenorrhea duration at least 12 months)
- •9.Negative pregnancy test for women with childbearing potential
- •10.Signing a written informed consent before any study related procedyres including phagogramprior to the phagogram
- •11.Affiliated to a national social security system and / or private health insuranceCovered by Health Insurance System and / or in compliance with the recommendations of National Law in force relating to biomedical research.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 35
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •1.Early Staphylococcus aureus Prosthesis Joint infection (?3months after the prosthesis implantation)
- •2.Other germ found in culture of joint fluid sample
- •3.No active anti Staphylococcus aureus bacteriophages in phagogram
- •4.Patients with ASA score = 4
- •5.Severe sepsis or Septic shock or hemodynamic instability
- •6.Immunosuppressed patients
- •7.Any known phage allergy
- •8.Medical history which in the opinion of the investigator would mean that the patient is unsuitable for participation in the study
- •9.Patient who, in the judgment of the Investigator, is likely to be non-compliant or uncooperative during the study, or unable to cooperate because of a language problem, poor mental development
- •10.Currently in exclusion period from a previous study
- •11.Concomitant participation to another interventional clinical trial.
- •12.Patients who are pregnant or breastfeeding. Patients should not be enrolled if they plan to become pregnant during the treatment period and 1 month after the last administration of study drug
- •13.Women/Men refusing to use an effective contraception during 1 month after the last administration of study drug
- •14.No possibility of contact in case of emergency
- •15.Minors, persons deprived of liberty by judicial or administrative decision, persons receiving psychiatric care and persons admitted to a health or social institution, to adult patient under legal protection or unable to express consent.
研究者
相似试验
进行中（未招募）
1 期
PhagoDAIR I : A Pilot, Multicenter, Randomized, Non Comparative, Double-Blind Study of Phage Therapy in Patients with Hip or Knee Prosthetic Joint Infection due to Staphylococcus aureus Treated with DAIR and Antibiotic Therapy.CTIS2024-516207-17-00Phaxiam Therapeutics29
终止
1 期
A Phase 1b/IIa trial to explore the combination of a new drug, PLX-7486, with gemcitabine in patients with advanced cancer (part 1b) and with advanced pancreatic ductal cancer and cancer-related pain (Part IIa)Advanced cancer/ Pancreatic Ductal AdenocarcinomaPancreatic Ductal AdenocarcinomaCancerISRCTN10978180HS Greater Glasgow and Clyde30
已完成
1 期
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic SolutionPrimary Open Angle GlaucomaOcular HypertensionNCT04284514Aerpio Therapeutics91
已完成
1 期
A First-in-human Study of Single Doses of PF-07328948 Which is Given to Healthy Adult ParticipantsHealthyNCT05654181Pfizer20
进行中（未招募）
1 期
A Phase I, open-label, multi-center study of radiation dosimetry, safety, and tolerability of extended lutetium (177Lu) vipivotide tetraxetan treatment in chemo-naïve adults with metastatic castration-resistant prostate cancerCancerISRCTN40970912ovartis Pharmaceuticals UK Limited106